BIO-UV Group (ALTUV) H1 2026 earnings summary

Executive summary

• Revenue for H1 2026 was €20.1M, nearly stable compared to €20.4M in H1 2025, reflecting resilience amid economic and geopolitical challenges.

• Profitability declined significantly, with EBITDA margin down to 12.5% from 17.3% in H1 2025, due to increased competition and a sharp rise in ruthenium costs.

• Net income for H1 2026 was €691K, with a net margin of 3.4%.

• International sales now represent over 45% of total revenue, with ongoing investments to strengthen presence in Asia and Scandinavia.

• Strategic focus remains on expanding Solutions and Services divisions, integrating the value chain, and maintaining strict cost control.

Financial highlights

• EBITDA for H1 2026 was €1.16M, compared to €2.01M in H1 2025.

• Operating income was €1.2M, with a margin of 5.8%.

• Diluted EPS for H1 2026 was €0.051, compared to €0.109 in H1 2025.

• Total assets at June 30, 2026, were €72.0M, with equity of €41.2M.

• Free cash flow nearly balanced at -€0.2M.

Outlook and guidance

• Full-year 2026 revenue target set at €38M–€42M, driven by Solutions and Services divisions.

• H2 2026 expected to benefit from export growth, especially in aquaculture and municipal/industrial water treatment.

• Continued focus on deleveraging, cost control, and margin preservation.

• Organizational changes in the commercial team are anticipated to yield benefits in 2027.